COVID-19 Antiviral Compounds

Track Code: 2022-GHOS-69724

Categories:
- Chemistry and Chemical Analysis
- Pharmaceuticals

Keywords:
- 3C-like protease
- 3CL protease
- 3CLpro inhibitor
- COVID-19
- Infectious Disease
- Pharmaceuticals
- SARS-CoV-2

Researchers at Purdue University have developed compounds that inhibit SARS-CoV-2 replication and outperform an approved therapy. Pfizer's Paxlovid and Merck's Molnupiravir are the only antiviral drugs available for individuals with severe COVID-19 symptoms. Purdue researchers are designing more potent compounds to address the continued need for effective COVID-19 therapies. The antiviral drugs developed by the Purdue researchers are 3CLprotease inhibitors that potently block SARS-CoV-2 replication. The best of these compounds are more potent than Pfizer's Paxlovid in enzyme inhibition and antiviral assays. The researchers expect the compounds to have drug-like properties.

Technology Validation: Enzyme inhibition and antiviral assays

Advantages:
- Effective inhibition of 3CLpro enzyme
- Potent antiviral activity

Applications:
- COVID-19 treatment

People:
- Ghosh, Arun K (Project leader)
- Sharma, Ashish

Intellectual Property:

Application Date: December 7, 2022
Type: PCT-Gov. Funding
Country of Filing: WO
Patent Number: (None)
Issue Date: (None)

Application Date: February 7, 2022
Type: Provisional-Gov. Funding
Country of Filing: United States
Patent Number: (None)
Issue Date: (None)

Contact OTC:

Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org